A functional SNP in miR-146a and genetic susceptibility to drug-resistant epilepsy.

OBJECTIVES: The study aimed to assess the relationship between the functional single nucleotide polymorphism (SNP) (rs57095329) of miR-146a, the progression of drug-resistant epilepsy (DRE), and the severity of the disease (seizure frequency) in a group of Egyptian children epilepsy patients.

SUBJECTS AND METHODS: 110 Egyptian children were recruited and divided into two groups, the epilepsy patients ( n  = 60) and the healthy control children ( n  = 50). The patient's group was equally subdivided into two subgroups: drug-resistant and drug-responsive epilepsy patients. Genomic DNA samples from all participants were screened for the incidence of the rs57095329 SNP of the miR-146a gene by the Real-Time PCR.

RESULTS: There was no statistical significance between epilepsy patients compared to controls    regarding the rs57095329 SNP genotypes and alleles. Contrarily, there was significant difference between the drug-resistant epilepsy and the drug-responsive cases ( P  < 0.05). The genotypes AG ( P  < 0.007, OR: 0.118, 95% CI (0.022-0.636)) and GG ( P  = 0.016, OR: 0.123, 95% CI (0.023-0.769)) were higher among the drug-resistant, while AA was higher among the drug-responsive patients. The alleles A and G were higher among all cases, with a statistically significant difference ( P  = 0.028, OR: 0.441, 95% CI (0.211-0.919)). A significant difference was reported in the dominant model (AA versus AG+GG) ( P  = 0.005, OR: 0.12395% CI (0.025-0.621)).

CONCLUSION: Therefore, miR-146a might be a potential therapeutic target for epilepsy treatment. The study was limited by the low number of young epileptic patients, the refusal of some parents to participate, and the incomplete medical history of some cases in the study, which forced their exclusion. More studies might be necessary to investigate other effective drugs to overcome the resistance issues induced by miR-146a rs57095329 polymorphisms.